Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients With Hereditary Hemorrhagic Telangiectasia (DIAMOND Trial)

NCT07623525 is registered in ClinicalTrials.gov with Diagonal Therapeutics, Inc. as lead sponsor.

NCT NCT07623525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients With Hereditary Hemorrhagic Telangiectasia (DIAMOND Trial)
Lead sponsor
Diagonal Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 4, 2026
Completion date
December 31, 2027
Enrollment
93 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia, pulmonary arterial hypertension